Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01891136 · ClinicalTrials.gov registry record · Early Phase 1
Oral Peanut Immunotherapy for Peanut Allergic Patients
A Early Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 36
- Enrollment target
NCT01891136: Completed Early Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
NCT01891136 is a Early Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 36 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01891136, a Early Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a study to determine if peanut oral immunotherapy (OIT) would desensitize or tolerize peanut allergic patients to peanuts in order prevent peanut allergic reactions.
Primary Outcome
Clinical desensitization will be measured with an oral food challenge (OFC) to peanut conducted while on OIT therapy.
Interventions
- DRUG Peanut protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-04 |
| Est. Completion | 2014-12 |
| Phase | Early Phase 1 |
What the finished NCT01891136 record still lists
NCT01891136 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 1 intervention - of which Peanut protein is the first listed.
NCT01891136 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01891136 about?
NCT01891136 is a clinical study titled "Oral Peanut Immunotherapy for Peanut Allergic Patients". This is a study to determine if peanut oral immunotherapy (OIT) would desensitize or tolerize peanut allergic patients to peanuts in order prevent peanut allergic reactions.
What is the current status of trial NCT01891136?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 36 participants. The study started on 2004-04. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01891136?
The interventions under investigation include: Peanut protein (DRUG).
Who is sponsoring clinical trial NCT01891136?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01891136's enrollment target sits among peer trials
36 712th of 2000 higher than 1,267 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia